SCHEMBL25333334

SCHEMBL25333334

Cc1ccc(-c2c(N)nn3ccc(C(F)(F)F)cc23)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAT2A P31153 4/20 0.51
GABRP O00591 4/20 0.43
GABRD O14764 4/20 0.43
GABRA1 P14867 4/20 0.43
GABRB1 P18505 4/20 0.43
GABRG2 P18507 4/20 0.43
GABRB3 P28472 4/20 0.43
GABRA5 P31644 4/20 0.43
GABRA3 P34903 4/20 0.43
GABRA2 P47869 4/20 0.43
GABRB2 P47870 4/20 0.43
GABRA4 P48169 4/20 0.43
GABRE P78334 4/20 0.43
GABRA6 Q16445 4/20 0.43
GABRG1 Q8N1C3 4/20 0.43
GABRG3 Q99928 4/20 0.43
GABRQ Q9UN88 4/20 0.43
NPC1 O15118 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25331835 0.88 MAPK14 (0.42) MAT2AGABRPGABRDGABRA1GABRB1
SCHEMBL25332245 0.86 NPC1 (0.40) MAT2AGABRPGABRDGABRA1GABRB1
SCHEMBL25332725 0.86 MAT2A (0.48) MAT2AGABRPGABRDGABRA1GABRB1
SCHEMBL25954950 0.86 MAT2A (0.54) MAT2AGABRPGABRDGABRA1GABRB1
SCHEMBL25332171 0.80 PIK3CD (0.37) MAT2ANPC1RAB9AUSP7NPBWR1
SCHEMBL31065865 0.79 MAT2A (0.52) MAT2AGABRPGABRDGABRA1GABRB1
SCHEMBL25335356 0.74 ALDH1A1 (0.39) MAT2AGABRPGABRDGABRA1GABRB1
SCHEMBL25332950 0.74 PKM (0.39) MAT2AGABRPGABRDGABRA1GABRB1
SCHEMBL31395944 0.74 KCNQ3 (0.50) MAT2AMAPTSLC2A1
SCHEMBL25954926 0.73 CDC7 (0.36) MAT2AUSP7HEXAHEXBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066351-A1 PYRAZOLO[1,5-A]PYRIDIN-2,3-YL AMIDES AS KV7 CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD (US) 2025-02-27 US disclosed
EP-4460501-A1 PYRAZOLO[1,5-A]PYRIDIN-2,3-YL AMIDES AS KV7 CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (US) 2024-11-13 EP disclosed
CN-118510777-A Pyrazolo [1,5-a ] pyridin-2, 3-ylamides as Kv7 channel activators 拜奥海芬治疗学有限公司 2024-08-16 CN disclosed
WO-2023133256-A1 PYRAZOLO[1,5-A]PYRIDIN-2,3-YL AMIDES AS KV7 CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD. (US) 2023-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066351-A1 PYRAZOLO[1,5-A]PYRIDIN-2,3-YL AMIDES AS KV7 CHANNEL ACTIVATORS KCNA7, KCNK17, KCNA1 MAT2A 3116/4885GABRP 258/4885GABRD 618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.